Feng Chen1, Kaier Zheng2, Frederik De Keyzer1, Raymond Oyen1, Yicheng Ni1
1Radiology, University of Leuven, Leuven, Brabant, Belgium; 2Radiology, BenQ Medical Center, Nanjing Medical University, Nanjing, China
Our randomized, controlled study demonstrated that the combination of a vascular disrupting agent with an antiangiogenic (ZdTha) enhanced overall antitumor efficacy due to synergistic effects. ZdTha induced cumulative tumor necrosis, and thus, significantly decreased tumor volume and reduced the viable tumor rim; ZdTha also reduced tumor vessel permeability and improved tumor hemodynamic indexes via a transient normalization of tumor vasculature induced by Tha. Finally, the ADC value at 12 d was shown to be an independent predictor of changes in tumor volume. These therapeutic effects were successfully tracked and evaluated with in vivo multiparametric MRI.